Isolator Technology for Aseptic Filling of High Potent Products - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Isolator Technology for Aseptic Filling of High Potent Products


PIERRE FABRE MEDICAMENT PRODUCTION owns a manufacturing site in the south of France, which has some of the largest experience worldwide with 22 years usage of isolator technology for aseptic filling of high potent freeze-dried injectable products.

Its newest generation of cytotoxic suites were built a few years ago to manufacture new products in compliance with worldwide CGMP and European ATEX regulation. All process operations: dispensing, compounding, filling, lyophilization, capping and external decontamination of the vial, are done under isolator technology. PFMP has developed an innovative filling line with Washing In Place system and Sterilization In Place system of the isolators with built-in Vaporized Hydrogen Peroxyde generator. These two new suites were granted “Most Advanced Facility of the Year” by European Outsourcing Awards in 2008.

PFMP proposes to its partners a full CDMO service with full Development of Product and Active Ingredient, Contract Manufacturing of API and Finish Product including freeze-drying cycle development. Its main objective is always to offer process technology innovation to manufacture future products and to guaranty the compliance with the evolution of the Quality criteria as well as the Environmental and Safety conditions.

PIERRE FABRE MEDICAMENT PRODUCTION
Contact: Franck PAVAN, Outsourcing & Business Development Manager
Email: franck.pavan@pierre-fabre.com
Website: www.aquitaine-pharm.com

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here